Browse Articles

Discover research articles across all indexed journals

Liver fat steers the outcome of advanced colorectal cancer

Nature Jul 01, 2026 DOI: 10.1038/d41586-026-01747-7

Exponentially Amplified Circularly Polarized Lasing from Chiral Carbon Dots

Advanced Materials Shurong Ding, Jin Bai, Meiyu He et al. Jul 01, 2026 DOI: 10.1002/adma.73789

ABSTRACT Circularly polarized luminescence (CPL) provides unique spin‐selective information, offering a crucial platform for the development of efficient spin‐dependent optical devices and advancing next‐generation photonic technologies. However, the intrinsically weak chiroptical response of CPL materials significantly limits their applications. To address this issue, this study proposes a strategy for the acid‐driven self‐assembly of carbon dots (CDs) into microhelical structures, which increases the dissymmetry factor ( g ‐factor) from less than 10 −5 to 6.5 × 10 −3 . Thus, circularly polarized laser emission was achieved for the first time in the field of CDs using an optical pumping system. The g ‐factor was exponentially amplified to 1.05, the threshold was as low as 28.91 mJ cm −2 , and the device exhibited excellent stability with no significant intensity attenuation after 15 h of operation. Using this high‐polarization laser, a rapid‐response circularly polarized laser logic gate system was successfully established. This study presents a novel material system and design model for developing high‐performance, low‐cost, carbon‐based chiral laser devices and integrated optical information processing devices.

Covalently Fused Nanofiber Aerogels With Exceptional Mechanical Robustness and Thermal Insulation for Deployable Space Systems

Advanced Materials Junjie Zheng, Junyan Zhang, Zhen Wang et al. Jul 01, 2026 DOI: 10.1002/adma.73564

ABSTRACT Nanofibrous aerogels exhibit an ultralow bulk density, making them highly desirable for lightweight aerospace structures. Nevertheless, these materials are often hampered by inherent physical brittleness, leading to severe structural failure under complex mechanical loads. To address this challenge, we developed a hybrid aerogel featuring core‐shell inter‐fiber junctions covalently fused via siloxane bonds, fabricated by in‐situ vapor‐phase polymerization of poly(vinylsilsesquioxane) (PVSQ) on a continuous and crosslinked native bacterial cellulose (BC) network. This unique architecture endows the aerogel (BC‐PVSQ) with outstanding mechanical adaptability and toughness, including >99% compressibility, bending resilience (curvature > 20 mm −1 ), robust tensile strength, and structural integrity over 10,000 shearing cycles. Significantly, it maintains low density (16.1 mg cm −3 ) and thermal conductivity (27.0 ± 0.2 mW m −1 K −1 ). As a proof of concept, we demonstrate the practical potential of the material for space‐deployable drag‐augmentation deorbiting spheres, enabling reversible folding compaction and reliable deployment, and for flexible habitat insulation, where it shows superior thermal insulation performance relative to conventional aerospace insulation materials under simulated Martian atmospheric conditions. This work successfully resolves the longstanding trade‐off between mechanical robustness and thermal insulation, laying a multifunctional technological foundation for next‐generation lightweight deployable systems designed for space environments.

MOF promotes venous thromboembolism in lung cancer by activating the YBX1–MALT1–NF-κB–PAI-1 axis, possibly through histone crotonylation

Journal of Biological Chemistry Yan Liu, Feng Yu, Jiuyang Jiang Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113348

Revolutionizing AML MRD: Gene-level kinetics to uncover chemoresistant clones and predict relapse risk via NGS.

Journal of Clinical Oncology Moin Makda, Shrinidhi Nathany, Hrithik Bagga et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.252

252 Background: Minimal residual disease (MRD) assessment in AML remains binary in practice, despite heterogeneity across genomic subtypes. We evaluated gene-specific MRD kinetics via serial NGS to define mutation-level clearance patterns, relapse risk, and resistance mechanisms. Methods: Sixty-nine newly diagnosed AML patients (median age 47, follow-up 25.7 months) were prospectively followed. Seventy percent harbored actionable mutations. Induction was predominantly azacitidine-venetoclax based; 71% underwent allogeneic transplant. Serial NGS tracked 189 DNA mutations, 12 RNA fusions, and 1 CNV. Among 60 patients with known regimens, 147 evaluable DNA mutations (57 patients) were analyzed for post-induction clearance and longitudinal kinetics. Results: Combined remission rate was 87%; relapse rate 27.5% (19/69). NGS detected MRD in 65% versus 22% by flow cytometry (concordance 47.8%, κ = 0.11). 67.6% of morphologic CR patients harbored persistent molecular disease. At mutation level, 65.3% achieved post-induction clearance; only 42.1% of patients achieved complete MRD negativity, reflecting resistant co-clones. Clearance varied sharply by gene. Signaling mutations showed high chemosensitivity: FLT3-ITD 87.5%, FLT3-TKD 75%, NRAS 80%, KIT 85.7%, RUNX1 100%, NPM1 78.9%. Epigenetic/metabolic mutations were resistant: IDH1/2 25.0% (OR 0.14, p = 0.0006), TP53 0% (p = 0.0014), and DTA genes 50%. Combined as “epigenetic modifiers” (DNMT3A/TET2/ASXL1/IDH1/2), clearance was 38.2% versus 73.5% for non-epigenetic mutations (OR 0.22, p = 0.0004), the strongest predictor of MRD persistence. Gene-specific relapse patterns refined risk. FLT3, IDH1/2, TP53, ASXL1, and BCOR relapsed largely in MRD-positive patients; no MRD-negative FLT3 or IDH1 patients relapsed. Conversely, WT1 (67% overall relapse) and KIT showed relapse even in MRD-negative states, highlighting genotype-dependent MRD limitations. NPM1 MRD negativity conferred excellent outcomes (0% relapse), while TP53 exhibited “smoldering persistence” with oscillatory VAF kinetics despite therapy. Functional hierarchy emerged: signaling/proliferative mutations cleared in 75% versus 35% for epigenetic/tumor suppressor lesions (p = 0.031), suggesting distinct resistance biology. Intensive regimens improved early clearance, whereas HMA+VEN+targeted combinations showed strongest late clearance and lowest relapse (16.7%). Conclusions: AML MRD is mutation-context dependent. Epigenetic modifier mutations define a chemoresistant MRD phenotype independent of ELN risk, while signaling mutations display paradoxical chemosensitivity. NGS-MRD outperforms flow cytometry , revealing actionable kinetic patterns informing transplant timing, targeted maintenance, and genotype-adapted surveillance. These data support a shift from binary MRD assessment to gene-specific kinetic modeling in AML.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus statins and the risk of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with type 2 diabetes mellitus (T2DM).

Journal of Clinical Oncology Sarina Ailawadi, Jennifer Elizabeth Murphy, Michael H. Storandt et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.139

139 Background: Statins have been shown to reduce the risk of HCC in high-risk populations with metabolic diseases. However, emerging data suggests that GLP-1 RA’s may also offer hepatoprotection by reversing metabolic and inflammatory drivers contributing to HCC development. Patients with T2DM are at an increased risk of metabolic associated steatotic liver disease (MASLD) and HCC. To our knowledge, no real-world studies have directly compared the effectiveness of GLP-1 RA’s and statins for prevention of HCC in patients with T2DM. In this study, we aim to compare the incidence of HCC and hepatic decompensation events in patients with T2DM treated with GLP-1 RA’s vs statins. Methods: We performed a retrospective cohort study using data from TriNetX, a healthcare database of over 150 million patients in the United States. Adult patients with T2DM were identified and stratified by use of GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, and lixisenatide) or statin (pitavastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin or lovastatin). Exposure groups were mutually exclusive with no overlap in GLP-1 RA or statin use. Propensity score matching was conducted between cohorts, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, MASLD, aspirin use, non-steroidal anti-inflammatory analgesic drug use, and other T2DM medications. Five-year incidence of HCC was compared between the GLP-1 RA and statin cohorts. In a subsequent analysis, hepatic decompensation events of ascites, hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), and esophageal varices (EV) were compared. Results: We identified 1,411,022 patients with T2DM, including 254,832 GLP-1 RA users and 1,156,190 statin users. After PSM, 219,984 patients were included in the analysis. There was no significant difference in the five-year incidence of HCC between the GLP-1 RA and statin cohorts (0.14% vs 0.15%, odds ratio (OR) 0.95, 95% confidence interval (CI)0.81-1.11, p =0.5). In the subsequent analysis, GLP-1 RA use was associated with a lower incidence of ascites (0.98% vs 1.99%, OR 0.84, 95% CI 0.46-0.51, p <0.001), HE (0.18% vs 0.22%, OR 0.84, 95% CI 0.74-0.96, p =0.01), and SBP (0.05% vs 0.1%, OR 0.52, 95% CI 0.42-0.65, p <0.001). There was no difference in incidence of EV (0.33% vs 0.35%, OR 0.94, 95% CI 0.85-1.04, p =0.25). Conclusions: In patients with T2DM at elevated risk for MASLD and HCC, we found that GLP-1 RA use was associated with significantly lower incidence of hepatic decompensation events compared to statin use. However, there was no significant difference in HCC incidence between the cohorts. Prospective studies are warranted to confirm the hepatoprotective effect of GLP-1 RA medications and evaluate long-term oncologic outcomes.

Atomic Evolution of Hydrogen Intercalation Wave Dynamics in Palladium Nanocrystals Revealed by Liquid-Phase Transmission Electron Microscopy

Journal of the American Chemical Society Daewon Lee, Sam Oaks-Leaf, Sophia B. Betzler et al. Jul 01, 2026 DOI: 10.1021/jacs.6c03937

A global assessment of reptiles in the skin trade

Scientific Reports Timothy J. Colston, Sophie. M. E. Marsh, J. Perran Ross et al. Jul 01, 2026 DOI: 10.1038/s41598-026-58104-x

Analysis of a decade of post-authorisation studies for medicines approved by the EMA

Nature Reviews Drug Discovery Caroline Voltz-Girolt, Guillem Wetherell Mateu, Carla Torre et al. Jul 01, 2026 DOI: 10.1038/d41573-026-00082-w

High Center‐of‐Mass, Multi‐Legged Soft Robots Powered by Geometrically Encoded Liquid Crystal Elastomer Arc Appendages

Advanced Materials Jong Bin Kim, Antonio Proctor Martinez, Yaoye Hong et al. Jul 01, 2026 DOI: 10.1002/adma.73794

ABSTRACT Biological appendages are paramount for locomotion by combining high compliance and versatile maneuverability. Yet most soft robots are largely confined to the contact surface due to their appendage‐free and single‐mode deformation, resulting in a low center‐of‐mass (CoM) and limited postural/spatial mobility. Here, we create soft robots utilizing liquid crystal elastomer (LCE) arc fibers as appendages to emulate the complex maneuvers of their biological counterparts. Geometrically encoding combined torsional and flexural modes allows these robots to transcend surface constraints via a naturally elevated CoM and enhanced maneuverability. Leveraging the kinetics and thermodynamics of the fiber deformation‐recovery cycles, we integrate the encoded fibers into the 3D‐printed body with vertical and horizontal rotational symmetries, inspired by the locomotion of the octopus and the golden wheel spider, respectively. Our model can elevate, lower, tilt, and rotate with substantial postural freedom. It can also be engineered to roll at 1.3 body lengths per second, climb a 32.5° incline, and traverse unstructured terrain. These feats are enabled by the large inertia generated by the inherent instability of the raised CoM and the effective ground anchoring of the appendages. These insights lay the foundation for customizable, high‐mobility soft robotic platforms that navigate complex real‐world environments.

Harnessing High‐Pressure CO <sub>2</sub> for Molecular‐Scale Interfacial Engineering in Sulfide‐Based All‑Solid‑State Lithium Metal Batteries

Advanced Materials Ruyi Fang, Xiaohan Fu, Xinxu Wang et al. Jul 01, 2026 DOI: 10.1002/adma.73554

ABSTRACT The rapid expansion of the low‐altitude economy has intensified the demand for energy storage with exceptional rate capability. Sulfide electrolytes, with high room‐temperature ionic conductivity and processability, are pivotal for next‐generation all‐solid‐state batteries (ASSBs), but their interfacial instability and the resulting low critical current density severely hinder high‐rate performance. Here, we propose a molecular‐level interfacial construction strategy using high‐pressure CO 2 to in situ engineer the Li 6 PS 5 Cl (LPSC) surface. Through precise regulation with concentrated CO 2 molecules, a nanoscale Li 2 CO 3 ‐rich layer with high Young's modulus and superior oxidant‑resistance is constructed. This designed interphase effectively suppresses parasitic reactions, enhances mechanical integrity, and homogenizes Li‐ion flux. Consequently, the modified LPSC exhibits exceptional dendrite‐suppression capability, achieving a critical current density of 7.76 mA cm −2 , and enables stable Li plating and stripping over 920 h at 5 mA cm −2 in symmetric cells. Furthermore, full cells paired with a high‐voltage LiNi 0.8 Co 0.1 Mn 0.1 O 2 cathode demonstrated outstanding rate capability at 5C with a power density of 3160 W kg −1 and maintained stable cycling over 500 cycles at 0.5C. This work proposes a simple and effective molecular‐scale interface engineering method to overcome the power limitation problem of sulfide‐based ASSBs.

Liver Tissueoid on‐a‐Chip Modeling Liver Regeneration and Allograft Rejection

Advanced Materials Abdul Rahim Chethikkattuveli Salih, Arne Peirsman, Danial Khorsandi et al. Jul 01, 2026 DOI: 10.1002/adma.202521178

ABSTRACT The lack of physiologically relevant in vitro models remains a limitation in liver transplantation research. Progress in organ‐on‐a‐chip technologies enables the generation of clinically translatable data in vitro. A vascularized liver tissueoid‐on‐a‐chip (LToC) model is engineered to replicate human liver tissue's structural and functional features for modeling liver regeneration and allograft rejection. The LToC comprises a microfluidic device containing donor‐matched human hepatic progenitor cells and intrahepatic portal vein endothelial cells embedded in a fibrin matrix and maintained in dynamic culture for 49 days. The system supports self‐assembly into a perfusable microvascular network and liver lobule‐like architecture, with &gt;95% cell viability, stable vascular integrity, and active hepatic function (albumin, urea, complement factors, and hepatocyte growth factor secretion). The mature tissueoid includes hepatocytes (CK18 + , albumin + , CYP2D6 + ), cholangiocytes (CK19 + , EPCAM + ), Kupffer cells (CD68 + ), stellate cells (PDGFR‐β + ), and endothelial cells (CD31 + ). Perfusion with allogeneic T cells induces cellular rejection, characterized by decreased viability, endothelial disruption, hepatic marker loss, HLA‐I upregulation, and a proinflammatory cytokine response (IL‐6, TNF‐α, IL‐1β, IFN‐γ, granzyme A and B, and perforin). The LToC provides a physiologically relevant platform for studying immune‐mediated liver injury, tissue regeneration, and allograft rejection, with potential applications in immunosuppressive drug testing and personalized transplant medicine.

HPV16 E2 protein possesses intrinsic helicase activity and sterically hinders E1 function through direct interaction

Journal of Biological Chemistry Ping Xu, Shuning Cai, Lihong Zhang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113143

Efficacy and safety of immune checkpoint inhibitors in recurrent platinum-resistant ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.

Journal of Clinical Oncology Aakash Pandit, Melisha Koirala Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.212

212 Background: Recurrent platinum-resistant ovarian cancer (PROC) is associated with poor prognosis and limited therapeutic options. While immune checkpoint inhibitors (ICIs) have been investigated in various combinations, individual trials have shown inconsistent survival benefits. We performed a systematic review and meta-analysis to evaluate the pooled efficacy and safety of ICI-based regimens in PROC. Methods: Conforming to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search of MEDLINE, Embase, Cochrane Central, and Scopus was conducted. Randomized controlled trials (RCTs) evaluating ICIs (monotherapy or combinations) versus standard of care (SOC) in PROC were included. Primary outcomes were overall survival (OS) and progression-free survival (PFS), reported as hazard ratios (HR). Secondary outcomes included objective response rate (ORR) and grade ≥3 treatment-related adverse events (TRAEs), reported as risk ratios (RR). Data were pooled using a random-effects model. Heterogeneity was assessed using the I² statistic. Results: Eight RCTs (n = 3,656) were identified. Pooled analysis demonstrated a significant improvement in OS with ICI-based regimens compared to SOC (HR 0.88; 95% CI, 0.79-0.97; p = 0.01; I² = 0%). While the overall PFS did not reach significance (HR 0.85; 95% CI, 0.67-1.09; p = 0.20; I² = 78%), a sensitivity analysis excluding the NINJA trial (monotherapy outlier) revealed a significant PFS benefit (HR 0.77; 95% CI, 0.68-0.87; p &lt; 0.0001; I² = 8%). In subgroup analyses, the combination of ICI plus chemotherapy significantly improved both OS (HR 0.83; 95% CI, 0.73-0.94) and PFS (HR 0.78; 95% CI, 0.67-0.91). Dual ICI therapy significantly improved PFS (HR 0.63; 95% CI, 0.42-0.94) and ORR (RR 2.95; 95% CI, 1.31-6.65). Safety analysis showed that ICI plus chemotherapy increased the risk of grade ≥3 TRAEs (RR 1.40; 95% CI, 1.10-1.78), whereas ICI monotherapy was associated with a lower risk of high-grade toxicity compared to chemotherapy (RR 0.29; 95% CI, 0.10-0.84). Conclusions: ICI-based therapies provide a significant survival benefit in patients with PROC, particularly when combined with chemotherapy. While these combinations increase the risk of high-grade toxicities, ICI monotherapy offers a better safety profile but lacks superior efficacy over standard chemotherapy.

Real-world efficacy of cabozantinib in combination with pemetrexed and carboplatin followed by pemetrexed-cabozantinib maintenance as first-line therapy for metastatic KRAS-mutant lung adenocarcinoma.

Journal of Clinical Oncology Vivek Agarwala, M.V. Chandrakanth, Amit Sharma et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.278

278 Background: KRAS-mutant advanced non-small-cell lung cancers (NSCLC) have shown suboptimal outcomes on standard chemo-immunotherapy. Cabozantinib, a multi-kinase inhibitor targeting MET, VEGFR, and AXL, may overcome resistance mechanisms here and enhance chemotherapy efficacy. We evaluated the clinical outcomes of a novel triplet regimen comprising pemetrexed, carboplatin, and cabozantinib in treatment-naïve patients with metastatic KRAS-mutant NSCLC. Methods: This was a multi-center prospective study of 25 patients with metastatic adenocarcinoma lung harboring KRAS mutations (EGFR/ALK/ROS1 negative), treated with 1st-line palliative chemotherapy with pemetrexed, carboplatin combined with cabozantinib 20mg once daily follwed by pemetrexed-cabozantinib maintenance. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included overall survival (OS), safety and tolerance. Results: The cohort (n = 25) had a median age of 61 years, predominantly male (68%) with history of smoking (72%). Most common sites of metastasis were bone (72%), lung (48%) and pleura (24%); 72% were ECOG PS 1 and 28% were PS 2. Most common KRAS variant was G12C (44%) followed by G12D (24%) and G12V (16%). Co-mutations were present in 36%; most common was TP53 mutation (28%). The ORR was 64% (16/25). At a median follow-up of 37 months, the median PFS was 10.1 months (95% CI: 7.0–16.0). The median OS was 17.2 months (95% CI: 8.8–NR). In multivariate analysis, baseline ECOG PS was the strongest predictor of outcomes, with PS 2 associated with significantly inferior PFS (p &lt; 0.01). Age &gt; 60 years (HR 2.49, p = 0.04) and presence of co-mutations (HR 2.25, p = 0.075) were independent risk factors for progression. Pleural metastasis was associated with significantly prolonged PFS (HR 0.31, p = 0.04). There was no significant difference in outcomes between KRAS G12C and non-G12C variants (p = 0.53). Fatigue was the most common all-grade toxicity (100%). Major grade III/IV toxicities were mucositis (28%), anemia (28%), neutropenia (16%), HFS (16%), diarrhea (12%), thrombocytopenia (8%) and renal dysfunction (8%). Two patients had hemoptysis related deaths. Cabozantinib dose escalation was feasible in 20% patients, interruption was needed in 28% and discontinuation in 12%. Conclusions: The combination of pemetrexed, carboplatin, and cabozantinib showed encouraging antitumor activity in KRAS-mutant NSCLC achieving numerically superior ORR and PFS to historical controls for standard chemo-immunotherapy with acceptable toxicity and safety. This real-world study suggests that adding anti-angiogenic/MET-targeted therapy to chemotherapy is a viable therapeutic strategy for KRAS-mutant patients, warranting validation in larger prospective trials.

Development and evaluation of a novel COI targeting primer set for metabarcoding-based enhanced detection of Scyphozoa (Cnidaria: Medusozoa) species

Scientific Reports Sung-Ah Kim, Sang-Eun Nam, Jae-Sung Rhee Jul 01, 2026 DOI: 10.1038/s41598-026-60462-5

Implantable hydrogel encapsulates ‘living therapeutics’

Nature Reviews Drug Discovery Katie Kingwell Jul 01, 2026 DOI: 10.1038/d41573-026-00096-4

Carbonyl‐Modulated Lowest Unoccupied Molecular Orbital Energy Directs Machine Learning‐Assisted Screening of Electrolyte Additives Toward Ultra‐Stable Zinc Metal Anodes

Advanced Materials Le Zhang, Shuyu Bi, Xijun Liu et al. Jul 01, 2026 DOI: 10.1002/adma.73811

ABSTRACT The commercialization of aqueous zinc‐ion batteries has long been hindered by side reactions stemming from zinc anode interfacial instability. Organic molecular additives offer an effective solution. Here, using lowest unoccupied molecular orbital (LUMO) energy and solubility as dual screening criteria, a novel high‐precision Organic Molecular Attention Prediction Graph Neural Network is developed to enable high‐throughput screening of organic additives. Through Shapley Additive exPlanations and density of states calculations, carbonyl electron localization is established as the dominant descriptor governing interfacial dynamics. α‐ketoglutaric acid (Ket) was selected as the optimal additive based on this principle. Strong coordination between its electronegative carbonyl groups enables the formation of a gradient‐structured solid‐electrolyte interphase on the Zn surface, resulting in uniform Zn 2+ flux distribution and significantly enhancing interfacial reversibility. Experimental demonstrates Zn||Cu cells achieve a high average Coulombic efficiency of 99.93% over 3500 cycles, while Zn||Zn cells exhibit unprecedented longevity of 4550 h (187 days) at 5.0 mA·cm −2 with calendar life exceeding 7000 h, and maintain stability even at ultra‐high current densities of 30 mA·cm −2 . Full cells paired with high‐loading (∼10 mg cm −2 ) ammonium vanadate cathodes retain over 80% capacity after 600 cycles. This study establishes a closed‐loop framework of screening, providing a new pathway for metal battery systems.

Bridging Synthesis and Device Performance in Perovskite Quantum Dot Light‐Emitting Diodes

Advanced Materials Zi‐Hao Zhang, Wan‐Shan Shen, Ya‐Kun Wang et al. Jul 01, 2026 DOI: 10.1002/adma.73516

ABSTRACT Perovskite quantum dots (PQDs) have emerged as promising emitters for next‐generation light‐emitting diodes (LEDs), owing to their exceptional color purity, tunable bandgaps, and high photoluminescence quantum yields (PLQYs). This review provides a comprehensive and insightful overview of the recent advances in PQD‐LEDs, with particular emphasis on the fundamental correlations between material synthesis, surface chemistry, and device engineering. We systematically examine the integrated “synthesis–surface–device” optimization framework, discussing advanced synthetic strategies, compositional and surface engineering for defect suppression and stability enhancement, and device‐level approaches to improve charge balance, radiative recombination, light outcoupling, and operational stability. By bridging foundational knowledge with material innovations and device design, this work offers a clear roadmap and step‐by‐step guidance for developing high‐performance PQD‐LEDs.

Structural basis of glucosinolate recognition and polyspecific transport by the glucosinolate transporter GTR1

Journal of Biological Chemistry Jing Nan, Hao Xu, Sisi Kang et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113190